6-KThe Wire
Telix Pharmaceuticals Ltd files 6-K
Filed Jul 2, 2026 · 1d ago · Accession 0001628280-26-046936
Plain English
Telix Pharmaceuticals Limited announced that the FDA has aligned with the company on the design of the ProstACT Global Phase 3 trial for TLX591. This alignment is expected to advance the trial's progression.
Filing details
- Company
- Telix Pharmaceuticals Ltd
- Ticker
- TLX
- CIK
- 2007191
- Form type
- 6-K
- Filing date
- Jul 2, 2026
- Report date
- Jul 1, 2026
- Document
- telix-6kforprostactglobalp.htm
- Size
- 926 KB
More from TLX
6-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSMay 21, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 23, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 21, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 20, 20266-KThe WireApr 14, 20266-KThe WireApr 14, 2026